|Day Low/High||81.15 / 82.82|
|52 Wk Low/High||62.01 / 87.07|
These may be uncharted waters, but they're not necessarily expensive.
Icahn may have a tough time finding interest in this behemoth.
Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.
Static doesn't work in this industry. Pipelines work.
Jim Cramer compares Allergan's growth to other pharma stocks.
Would get drugs to market faster and possibly more cheaply.
The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
He's never really been a stock market guy anyway.
U.S. stocks fluctuated Wednesday after President-elect Trump targets the biotech industry in his first press conference since July.
The terror that the futures struck, rightly or wrongly, has disappeared.
"I don't feel Tuesday...Tuesday has no feel." -- Seinfeld I started the day with some food for thought -- on the changing channels of retail distribution. In this opener please pay some attention to not only the ramifications for retail stocks but ...
Animal health and oncology deal activity is heating up in 2017.
I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure. In other words, I am sticking to my script...
You have to think that if these stocks were so high once, then it's likely they will be again.
Disney and Goldman are doing a lot of the heavy lifting.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
The popular dividend strategy has been a lucrative investment in 2016, but what's in store for 2017?
There is a dearth of retail experience on its board during a period of major industry disruption.